D'Angio Paul 4
4 · NexImmune, Inc. · Filed Feb 19, 2021
Insider Transaction Report
Form 4
NexImmune, Inc.NEXI
D'Angio Paul
Director
Transactions
- Conversion
Common Stock
2021-02-17+19,627→ 19,627 total - Conversion
Common Stock
2021-02-17+4,110→ 23,737 total - Conversion
Common Stock
2021-02-17+4,110→ 27,847 total - Conversion
Series A Preferred Stock
2021-02-17−19,627→ 0 total→ Common Stock (19,627 underlying) - Conversion
Series A2 Preferred Stock
2021-02-17−4,110→ 0 total→ Common Stock (4,110 underlying) - Conversion
Series A3 Preferred Stock
2021-02-17−4,110→ 0 total→ Common Stock (4,110 underlying)
Footnotes (3)
- [F1]The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis.
- [F2]The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering.
- [F3]Not applicable.